Literature DB >> 18067006

Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.

Nicola Giuliani1, Vittorio Rizzoli.   

Abstract

Bone destruction is the hallmark of multiple myeloma (MM) due to the high capacity of malignant plasma cells to induce a severe imbalance of bone remodeling. Growing evidences suggest that MM cell interactions with bone marrow (BM) osteoblast have a critical role in the pathophysiology of osteolytic lesions. Indeed histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation together with osteoclast activation. Recently, the biological mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated, underlying the main role of the block of osteoblast differentiation in the development of bone lesions. In this article, we summarize the main mechanisms regulating MM cell and osteoblast interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067006     DOI: 10.1080/10428190701648281

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  24 in total

Review 1.  Dickkopf1: a tumor suppressor or metastasis promoter?

Authors:  Mitchell E Menezes; Daniel J Devine; Lalita A Shevde; Rajeev S Samant
Journal:  Int J Cancer       Date:  2011-11-02       Impact factor: 7.396

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Effects of DKK1 overexpression on bone metastasis of SBC-3 cells.

Authors:  Hailin Pang; Ningqiang Ma; Weiwei Shen; Qiang Zhao; Jianlin Wang; Lian Duan; Wenjuan Chen; Ning Zhang; Zhengwei Zhao; Lili Liu; Helong Zhang
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 4.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

Review 5.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

6.  A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.

Authors:  Kimberly Noonan; Luigi Marchionni; Judy Anderson; Drew Pardoll; G David Roodman; Ivan Borrello
Journal:  Blood       Date:  2010-07-27       Impact factor: 22.113

Review 7.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

Review 8.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

9.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

Review 10.  Mechanisms of osteolytic and osteoblastic skeletal lesions.

Authors:  G David Roodman; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.